Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Therapy of hepatitis C virus-associated glomerulonephritis: current approaches Fabrizi F; Lunghi G; Messa P; Martin PJ Nephrol 2008[Nov]; 21 (6): 813-25The most frequent kidney disease associated with chronic hepatitis C virus (HCV) infection is type I membranoproliferative glomerulonephritis (MPGN) in patients with type II mixed cryoglobulinemia. The principal clinical manifestations of glomerular disease in HCV-infected patients are the presence of proteinuria and microscopic hematuria with or without impaired kidney function. Various approaches have been tried for the treatment of HCV-associated glomerulonephritis, including immunosuppressive therapy (corticosteroids and cytotoxic agents), plasma exchange and antiviral agents. Limited data exist regarding antiviral treatment of HCV-associated glomerulonephritis, whereas immunosuppressive agents have been suggested for cryoglobulinemic kidney disease. A recent meta-analysis of controlled clinical trials (CCTs) suggested that standard interferon (IFN) doses were more effective than immunosuppressive agents in lowering proteinuria of patients with HCV-related cryoglobulinemic glomerulonephritis (odds ratio 3.86; 95% confidence interval, 1.44-10.33; p=0.007). However, data for follow-up were not given. Two distinct approaches should be considered for the treatment of HCV-associated cryoglobulinemic glomerulonephritis according to the level of proteinuria and kidney failure. Preliminary studies with rituximab therapy of HCV-related cryoglobulinemic glomerulonephritis have given encouraging results, even if a point of caution is important, because rituximab use may be associated with activation of various infections, including HCV.|Antibodies, Monoclonal, Murine-Derived[MESH]|Antibodies, Monoclonal/therapeutic use[MESH]|Antigens, CD20[MESH]|Antiviral Agents/*therapeutic use[MESH]|Clinical Trials as Topic/methods[MESH]|Drug Therapy, Combination[MESH]|Glomerulonephritis/*drug therapy/etiology[MESH]|Hepacivirus/isolation & purification[MESH]|Hepatitis C, Chronic/*complications/drug therapy/virology[MESH]|Humans[MESH]|Immunologic Factors/*therapeutic use[MESH]|Immunosuppression Therapy/*methods[MESH]|Interferons/therapeutic use[MESH]|Ribavirin/therapeutic use[MESH]|Rituximab[MESH] |